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Running Title: Confounding Issues in Aminoglycoside Dosing

Abstract: Aminoglycoside antibiotics are usually administered by multiple short intravenous
infusions at fixed intervals. Today, equations reported 35 years ago by Sawchuk and Zaske are
still the cornerstone of methods used for determination of patient-specific pharmacokinetic
parameters of aminoglycosides and individualization of drug dosage regimens in many clinical
settings. Additionally, these methods are included in many clinical pharmacology curricula in
pharmacy and other related fields. However, there are a few issues with regard to the application
and/or modification of this method in clinical settings, which may result in some confusion
among novice clinicians. For example, serum samples collected from different intervals at steady
state, instead of samples obtained during the same interval, require special manipulation of
sampling time before they can be used for estimation of pharmacokinetic parameters.
Furthermore, there are various ways that the original equations are modified or simplified, which
can result in some degree of error in the estimates of pharmacokinetic parameters and ensuing
dosage regimen calculations. Simulation data presented here indicate that in some cases, these
errors may be substantial, depending on the length of short infusion, half life of the drug, and the
dosage interval. For instance, using equations developed for intravenous bolus mode of
administration, ignoring the short infusion, may result in ≥ 25% error for a typical patient and
dosing scenario. Although experts may use modified equations, understanding their error
ramifications, these modifications may be confusing to the novice clinicians. Therefore, it is
recommended that exact equations developed specifically for multiple intravenous infusions be
used without any modification, particularly in settings where clinicians are being trained.
Key Words: Aminoglycoside dosing, clearance, clinical pharmacokinetics, elimination rate
constant, intermittent intravenous infusion, patient-specific pharmacokinetics, peak and trough,
volume of distribution.
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INTRODUCTION
Aminoglycosides are bactericidal antibiotics, used systemically in the treatment of
serious gram negative infections, such as pneumonia or bacteremia [1]. The most widely used
systemic aminoglycosides include amikacin, gentamicin, tobramycin, and netilmicin. The
efficacy and toxicity of these drugs are related to their plasma concentrations [2, 3].
Additionally, the pharmacokinetics of aminoglycosides are subject to substantial intra- and interpatient variability [4, 5]. Therefore, their dosing in most cases is guided by therapeutic drug
monitoring. The absorption of aminoglycosides after oral administration is generally poor.
Therefore, for systemic effects, they are administered mostly by intramuscular or intravenous
injections. However, the intermittent intravenous (iv) infusion of these drugs over 30-60 min at
fixed intervals is by far the most common method used for their administration.
The intermittent iv infusion method is a unique method of drug administration, which is
different from both constant iv infusion and iv bolus injection. Therefore, specific equations are
used for calculation of some of the kinetic parameters after this mode of administration. Thirty
five years ago [6], Drs. Ronald Sawchuk and Darwin Zaske, from the University of Minnesota
College of Pharmacy, reported a general method for estimation of the patient-specific kinetic
parameters of aminoglycosides and the design of dosage regimens. To date, this method is still
the cornerstone of aminoglycoside dosage individualization in most clinics, although extended
interval aminoglycoside dosing was also added later to the methods of aminoglycoside
administration [7]. Therefore, the so-called Sawchuk-Zaske method is one of the major methods
used by clinicians to initiate and/or adjust aminoglycoside dosing. Additionally, it is the main
method that is taught in pharmacy and medicine curricula.
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Despite its wide acceptance, there are some issues with regard to the application and/or
modification of this method in clinical settings, which may result in some confusion and errors in
estimation of pharmacokinetic parameters and any patient-specific dosage regimens designed
from the calculations. Although most of these issues may be viewed as minor nuisances for
expert clinicians, they may pose significant sources of confusion for future clinicians during their
early stages of understanding these methods. The purpose of the current communication is,
therefore, to address these confounding issues and their potential impact on the estimation of the
patient-specific pharmacokinetic parameters and/or dosing of patients, in a style that may be used
for education of novice clinicians. Where modifications of the original equations are discussed,
simulations are used to provide data on the degree of error associated with these modifications.
This communication is not intended to be an exhaustive review of the aminoglycoside
pharmacokinetics, pharmacodynamics, population-based initial dosing, or extended-interval
dosing. For the latter purposes, the reader is referred to excellent book chapters [8-10] and
review articles [11-13] on these topics, which were published recently.

HOW

IS

INTERMITTENT

INTRAVENOUS

INFUSION

DIFFERENT

FROM

INTRAVENOUS BOLUS ADMINISTRATION?
When a drug is administered by the iv bolus method, the entire dose is introduced into the
systemic circulation relatively rapidly (within a few seconds to minutes), resulting in a maximum
plasma concentration (Cmax) being achieved almost immediately (Co). With a short iv infusion,
however, each dose is administered over a short, constant rate infusion, resulting in a lower Cmax,
compared with the administration of the same dose of the drug by the iv bolus method (Fig. 1).
However, as demonstrated in Fig. 1, the minimum plasma concentration before the
4

administration of the next dose (Cmin) using the short infusion method is expected to be higher
than that after the iv bolus dose. Overall, a lower Cmax and higher Cmin mean a lower fluctuation
in the plasma concentrations after intermittent short iv infusion, compared with multiple bolus
doses. Obviously, with linear pharmacokinetics (i.e. where clearance and volume of distribution
remain the same with different plasma concentrations), total exposure (AUC) for both cases will
be the same. Although more inconvenient than iv bolus dose, this method has the advantage of
avoiding high initial concentrations which may produce toxicity. An additional reason for using
this method for aminoglycosides is to allow time for distribution of the drug into the tissues,
allowing the use of simple one-compartment model kinetics.

ESTIMATION OF PATIENT-SPECIFIC PHARMACOKINETIC PARAMETERS
The normal dosing of aminoglycosides is via administration of multiple short (0.5-1 h) iv
infusions of the drug at fixed intervals (τ). This results in a Cmax, attained at the end of the short
infusion and a Cmin, attained at the end of dosage interval before the next dose is administered
(Fig. 1). Although several samples, belonging to the same or multiple intervals, may be taken
from a patient and subjected to pharmacokinetic software for analysis, a common method is
obtaining the kinetic parameters by subjecting the data from a peak and a trough sample to the
Sawchuk-Zaske method (Fig. 1). The peak concentration is measured in a sample taken some
time (normally at least 30 min after a 0.5 h infusion or 15-30 min after a 1 h infusion) after the
infusion is stopped. Regardless of the length of infusion, it is recommended that the peak sample
be taken at ≥ 1 h after the start of infusion to avoid the distribution phase. A trough concentration
is normally taken ≤ 30 min before the next dose is administered (e.g., 30 min, 15 min, or
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immediately before the next dose). In the following sections, the use of peak and trough samples
in obtaining patient-specific kinetic parameters is explained.
Estimation of Elimination Rate Constant: Peak and Trough from the Same or Different
Dosage Intervals?
Although in their original study [6], Sawchuk and Zaske obtained four plasma samples
from each patient at steady state (one predose sample and three additional samples after the next
dose), most of the applications of this method have been based on obtaining only two samples
(peak and trough) from the patient. The following equation is then used for estimating k:
!"#$

𝑘=

!"  (!"#$%!)
∆!

(1)

where Δt is the difference between the time of peak (tpeak) and time of trough (ttrough) samples
(ttrough–tpeak), assuming they belong to the same interval. If the samples are taken after the first
dose, the peak and trough samples must belong to the same interval. Therefore, there is no
confusion about the estimation of k using Equation (1). Additionally, if the peak and trough
samples are taken at steady state from the same dosage interval, the use of the above equation is
clear. The confusion arises, however, when the peak and trough belong to two different dosage
intervals at steady state. This situation arises when, for the sake of convenience and/or
expediency, a trough sample is taken first at some interval at steady state, followed by a peak
sample collected after the administration of the next dose (Fig. 2). The idea is that at steady state,
the peak and trough samples for repeating dosage intervals are theoretically identical. Therefore,
the trough sample taken before the next dose, when the peak sample is taken, should be similar
to the trough sample if it had been taken at the end of the next dose. Obviously, the use of the
actual times written in the patient’s chart for application to Equation (1) would yield an incorrect
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k value with a negative sign (ttrough–tpeak would be negative) because the slope of the increasing
line (from trough to peak) is positive. Therefore, some manipulation of time is needed for
estimation of k using Equation (1) and the peak and trough samples from two different intervals:
either the clock time of the trough sample should be extended by one dosage interval or the clock
time of the peak sample moved back by one dosage interval (Fig. 2). This issue is demonstrated
using an example listed below.
Example
Gentamicin was administered to a patient by a short 0.5-h infusion of 80 mg every 8 h
starting on 4/26/11. Excerpts from the patient’s chart regarding the drug administration and
laboratory results for peak and trough concentrations of gentamicin are reported in Fig. 3. As
demonstrated in the chart data (Fig. 3) and graphical presentation of the laboratory report (Fig.
2), the trough sample is taken 0.5 h before the 0930 dose on 4/28/11, whereas the peak sample is
taken 1.0 h after the 0930 dose at 1030. Therefore, the reported peak and trough concentrations
belong to two different dosage intervals. Ignoring this fact results in the following inaccurate
estimation of k:
ln  (
𝑘=

𝑃𝑒𝑎𝑘
) ln  (4.68)
𝑇𝑟𝑜𝑢𝑔ℎ
1.37 = −0.819  h-‐1
=
∆𝑡
9 − 10.5

A potential mistake by novice clinicians is to use (10.5 – 9) in the denominator to obtain a
positive value for k (in this case 0.819 h-1). Whereas a k value of –0.819 hr-1 represents an
increase in the plasma concentration from trough to peak, a value of 0.819 hr-1 represents a
decrease in the concentration from peak to trough in 1.5 h. As stated above, in such cases, an
accurate estimation of k requires either addition of one dosage interval to the trough time or
subtraction of one dosage interval from the peak time, as demonstrated in Figs. 2 and 3.
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Consequently, Equation (1) along with the manipulated times may be used for the accurate
estimation of k:
ln
𝑘=

𝑃𝑒𝑎𝑘
4.68
ln 1.37
𝑇𝑟𝑜𝑢𝑔ℎ
=
= 0.189  h-‐1
∆𝑡
17 − 10.5

or
ln  (
𝑘=

𝑃𝑒𝑎𝑘
) ln  (4.68)
𝑇𝑟𝑜𝑢𝑔ℎ
1.37 = 0.189  h-‐1
=
∆𝑡
9 − 2.5

A third approach would be to calculate the time within interval for the peak (tpeak) and trough
(ttrough) samples independently. For this calculation, tpeak is 1 h because the peak sample was
taken 1 h after the 0930 dose at 1030 (1030 – 0930) (Fig. 3). Additionally, ttrough is 7.5 h because
it was taken 7.5 h after the 0130 dose at 0900 (0900 – 0130) (Fig. 3). Subsequently, Δt in
Equation (1) (ttrough – tpeak) becomes equal to 6.5 h (7.5 – 1.0).
Estimation of Volume of Distribution: Based on Cmin and Cmax or Peak and Trough?
Estimation of volume of distribution (V) after multiple constant iv infusion is not as
simple as that after the iv bolus administration. In their original article [6], Sawchuk and Zaske
used the following equation for determination of V after multiple iv infusions:

𝑉=

!!
!

×

(!!!

!!!!"#

)

(!!"# !!!"#$%&# !

!!!"#

)

(2)

where Ro, tinf, Cmax, and Cpredose are the rate of short infusion, duration of short infusion,
maximum plasma concentration, and the plasma concentration before the administration of the iv
infusion, respectively. The rate of short infusion (Ro) is equal to dose/tinf. Equation (2) is
applicable to any dosage interval, including those after the first dose and at steady state.
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Realizing that the Cpredose for the first dose is equal to zero, Equation (2) is simplified after the
first dose:

𝑉=

!!
!

×

(!!! !!!!"# )

(3)

!!"#

Additionally at steady state, Cpredose is the same as the steady-state minimum concentration
!
!
(𝐶!"#
), and Cmax is equal to 𝐶!"#
:

𝑉=

!!
!

×

(!!! !!!!"# )
! !! ! !
(!!"#
!"#

!!!!"#

)

(4)

!
!
Equation (4) may be rearranged to contain only 𝐶!"#
in the denominator, instead of both 𝐶!"#
!
and 𝐶!"#
:

𝑉=

!!
!

(!!! !!!!"# )

× !!

!"# (!!!

!!" )

(5)

Both Equations (4) and (5) would give an accurate and identical estimate of V using steady state
!
data. However, in practice, rarely 𝐶!"#
is directly sampled and measured. Instead, a peak sample

is taken between 15-60 min after the end of infusion. Therefore, the peak has to be back
!
extrapolated to obtain 𝐶!"#
(Fig. 1) using the following equation:

!"#$

!
𝐶!"#
= ! !!∆!

(6)

!
where Δt is equal to the difference in time between the occurrence of 𝐶!"#
(at the end of
!
infusion) and the peak sampling time. For the example above, 𝐶!"#
is 5.14 mg/L, as

demonstrated below:
!
𝐶!"#
=

4.68
𝑒 !!.!"#×!.!

= 5.14  mg/L

!
Additionally, the 𝐶!"#
may be obtained from the following equation if the trough sample is taken

at a time before the end of interval:
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!
𝐶!"#
= 𝑇𝑟𝑜𝑢𝑔ℎ×𝑒 !!∆!

(7)

!
where Δt in Equation (7) is the time difference between the occurrence of 𝐶!"#
at the end of
!
interval and trough sampling time. In the above example, 𝐶!"#
is equal to 1.25 mg/L:
!
𝐶!"#
= 1.37×𝑒 !!.!"#×!.! = 1.25  mg/L

Using the above values in Equation (4), the V for our example case is 19.0 L:
𝑉=

160
(1 − 𝑒 !!.!"#×!.! )
×
= 19.0  L
0.189 (5.14 − 1.25×𝑒 !!.!"#×!.! )

Additionally, an identical value of V may be obtained using Equation (5):
𝑉=

160
(1 − 𝑒 !!.!"#×!.! )
×
= 19.0  L
0.189 5.14×(1 − 𝑒 !!.!"#×! )

However, some clinicians may use the actual peak and/or trough values, instead of
!
!
extrapolated 𝐶!"#
and 𝐶!"#
, for estimation of patient-specific V. If one uses this approach in the

example above, the calculated V will be 22.2 L using Equation (4):
160
(1 − 𝑒 !!.!"#×!.! )
𝑉=
×
= 22.2  L
0.189 (4.68 − 1.37×𝑒 !!.!"#×!.! )
!
Additionally, using peak concentration in Equation (5), instead of 𝐶!"#
, results in a V of 20.9 L:

𝑉=

160
(1 − 𝑒 !!.!"#×!.! )
×
= 20.9  L
0.189 4.68×(1 − 𝑒 !!.!"#×! )

!
!
Using the peak and trough values, instead of 𝐶!"#
and 𝐶!"#
, in Equation (4) and using peak
!
value, instead of 𝐶!"#
, in Equation (5) resulted in 17% and 10% overestimation of V,

respectively. Obviously, the magnitude of overestimation will be dependent on the differences in
!
!
time between the peak and 𝐶!"#
and between the trough and 𝐶!"#
, in addition to the magnitude

of k: the larger the time difference and/or the k, the larger is the error in overestimation of V.
!
The degree of overestimation of V using peak concentration, instead of 𝐶!"#
, in Equation

(5) is demonstrated in Fig. 4 as a function of half life for Δt (difference in time between the end
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of infusion and peak) values of 0.25, 0.5, and 1.0 h. As expected, the degree of error is highest
for short half lives (large k values) and long Δt values. These simulations (Fig. 4) indicate that
when Δt is 0.25 h, the degree of error is less than 10% as long as the half life is ≥ 2 h, which is
!
the case for most patients. Therefore, using peak value, instead of 𝐶!"#
, when Δt is 0.25 h is not

expected to create a sizeable error in most cases. However, for Δt values of 0.5 and 1.0 h, errors
greater than 10% may occur even with short half lives of ~2-3 h. Therefore, it may be prudent to
!
use the extrapolated 𝐶!"#
when Δt is ≥ 0.5 h.

Estimation of Volume of Distribution: Assuming Intravenous Bolus Dosing
Another approximation in the estimation of V after multiple iv infusions is to assume the
data are obtained after the iv bolus (instead of short infusion) dosing, hence using the following
equation:
!"#$

𝑉=!

!"# !!!"#$%&#

(8)

where Cmax and Cpredose are defined before. The above equation may be rewritten for the first dose
and at steady state:
!"#$

𝑉=!

!"#

𝑉 = !!

                First  Dose

!"#$

!
!"# !!!"#

                    Steady  State

(9)
(10)

Application of this approximation to the above example would result in a V of 20.6 L:
𝑉=

80
= 20.6  L
5.14 − 1.25

Again, this approximation always causes overestimation of V (in this case by ~8%). The degree
of overestimation of V using the equations for bolus route is dependent on the magnitude of
difference between Co (maximum plasma concentration if the drug were administered by iv
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bolus route) and Cmax. This means the longer the length of the infusion or the faster the decline in
the plasma concentration (shorter half life), the larger is the difference between the Co and Cmax
values, hence resulting in a higher overestimation of V.
The degree of overestimation of V using Equation (10), instead of Equation (4) or (5), is
demonstrated in Fig. 5 for infusion times of 0.5 and 1.0 h and dosage intervals of 4, 6, and 8 h.
These simulations indicate that in addition to the half life and tinf, the degree of overestimation is
also dependent on the dosage interval: Given the same tinf and k, the degree of error is more
substantial for shorter dosage intervals (Fig. 5). Additionally, these simulations indicate that
when tinf is equal to 1 h, the degree of overestimation using Equation (10) is high even when the
half life is relatively long. Therefore, the use of Equation (10) for estimation of V does not seem
appropriate for infusion times of ≥ 1 h.
Estimation of Volume of Distribution: Based on Modified Sawchuk-Zaske Equations
In addition to the above approximations (using peak and trough values in the SawchukZaske method or using iv bolus equations), some clinicians may use different modifications of
the Sawchuk-Zaske method. For example, at Texas Tech School of Pharmacy, some faculty
clinicians advocate the use of the following equation:

𝑉=

!!
!

(!!! !!!!"# )

× (! !

!
!"# !!!"# )

(11)

!
The above equation is different from the exact Sawchuk-Zaske equation by using 𝐶!"#
instead of
!
𝐶!"#
𝑒 !!!!"# in the denominator. Using the above equation for the example data (Cmax of 5.14 and

Cmin of 1.25 mg/L) would yield some degree of overestimation:
𝑉=

160 (1 − 𝑒 !!.!"#×!.! )
×
= 19.6  L
0.189
(5.14 − 1.25)
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Again, the degree of overestimation is dependent on both the elimination rate constant and the
length of infusion, in addition to the length of dosage interval. However, in contrast to the
approximations based on Equation (10) (Fig. 5), an increase in the half life causes an increase in
the degree of overestimation using Equation (11) approximation (Fig. 6). This is because an
increase in the half life, keeping τ constant, also causes an increase in the degree of accumulation
of the drug, making the effect of approximation more prominent. Still, similar to Equation (10)
approximation, the overestimation is larger for the tinf of 1 h, compared with that for the tinf of 0.5
h (Fig. 6). Additionally, the shorter intervals cause a higher degree of error (Fig. 6).
Nevertheless, this type of approximation appears to introduce little error for the tinf of 0.5 h,
especially if τ is ≥ 6 h (Fig. 6). However, when the tinf is 1 h, substantial errors may be
encountered, depending on the half life and τ (Fig. 6).
Estimation of Clearance
Once the k and V values are estimated above, the clearance (Cl) of aminoglycosides may
be simply obtained using the following equation:
𝐶𝑙 = 𝑘×𝑉

(12)

The degree of error in the estimation of Cl is obviously dependent on the errors associated with
the estimation of k and V as discussed above.

DESIGN OR ADJUSTMENT OF DOSAGE REIMENS BASED ON THE SAWCHUKZASKE EQUATIONS
The Sawchuk-Zaske equation for the determination of V at steady-state may be
rearranged to estimate the infusion rate (dose/tinf) necessary to achieve desired maximum and
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minimum concentrations. Additionally, the desired maximum and minimum concentrations and
the drug elimination rate constant may be used to estimate an appropriate dosage interval. To
design a dosage regimen (dosage interval and infusion rate), one may use the initial kinetic
parameters obtained based on the population data or the patient-specific parameters. Estimations
of dosage interval and infusion rate are explained in more detail below.
Estimation of Dosage Interval: Based on Desired Cmin and Cmax or Peak and Trough?
One of the sources of confusion in the literature regarding aminoglycoside dosing is that
!
the goal of therapy in most cases is stated based on peak and trough values [1], rather than 𝐶!"#
!
and 𝐶!!"
. Therefore, in designing the dosage regimens, it must be decided whether the goal is to
!
!
achieve a certain 𝐶!"#
and 𝐶!"#
or a certain peak and trough. Obviously, if the goal is stated in
!
terms of peak and trough, it must be defined in terms of the distances between the peak and 𝐶!"#
!
and between the trough and 𝐶!"#
. The following equation may be used to estimate a τ based on

desired maximum and minimum concentrations:
!

𝜏=

!
!"  ( !"#
! )
!!"#

!

+ 𝑡!"#

(13)

!
!
For example, in the above case, if the goal is to achieve a 𝐶!"#
of 8 mg/L and a 𝐶!"#
of ≤ 2

mg/L, the calculated τ will be 7.83 h:

𝜏=

8
ln  (2)
0.189

+ 0.5 = 7.83  h

One needs to round the calculated τ to a practical τ, in this case 8 h. However, if the goal is
expressed as desired trough and peak concentration, the following equation may be used:
𝜏=

!"  (

!"#$
)
!"#$%!

!

+ 𝑡!"# + ∆𝑡!"#$ + ∆𝑡!"#$%!

(14)
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where ∆𝑡!"#$ and  ∆𝑡!"#$%! represent, respectively, the difference in time between the peak and
maximum concentration and between the trough and minimum concentration at steady-state. If
we assume that the desired peak and trough are based on a situation when peak is taken 0.5 h
after the end of infusion and trough is taken immediately before the next dose, the ∆𝑡!"#$
and  ∆𝑡!"#$%! values will be 0.5 h and zero, respectively:

𝜏=

8
ln  (2)
0.189

+ 0.5 + 0.5 + 0.0 = 8.33  h

The calculated τ in this case is more than 8 h. Rounding down the calculated τ to 8 h means that
the expected trough value using this regimen will be higher than 2 mg/L.
Estimation of Infusion Rate: Based on Desired Cmax or Peak?
Similar to the estimation of τ above, the estimation of infusion rate (Ro or dose/tinf) is also
!
dependent on the desired therapeutic goal. If the goal is based on the desired 𝐶!"#
, then the

following equation is used:
!
𝑅! = 𝐶!"#
×𝑉×𝑘×

𝑅! = 8×19×0.189×

(!!! !!" )
(!!! !!!!"# )

(15)

(1 − 𝑒 !!.!"#×! )
= 254  mg/h
(1 − 𝑒 !!.!"#×!.! )

!
Based on the above calculations, the new dose (dose = Ro x tinf) to achieve a 𝐶!"#
of 8 mg/L is

~130 mg (dose = 254 x 0.5), administered over a 0.5 h short infusion. On the other hand, if the
goal is to achieve a peak of 8 mg/L at 0.5 h after the end of infusion, one may use the following
equation:
!"#$

𝑅! = ! !!∆! ×𝑉×𝑘×
𝑅! =

8

𝑒

×19×0.189×
!!.!"#×!.!

(!!! !!" )
(!!! !!!!"# )

(16)

(1 − 𝑒 !!.!"#×! )
= 280  mg/h
(1 − 𝑒 !!.!"#×!.! )
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This means a dose of 140 mg administered over a 0.5 h short infusion. Obviously, a peak of 8
!
mg/L in this case means a 𝐶!"#
of 8.8 mg/L:
!
𝐶!"#
=

𝑃𝑒𝑎𝑘
8
= !!.!"#×!.! = 8.8  mg/L
!!∆!
𝑒
𝑒

!
The difference in Ro (or dose) between the two methods (using 𝐶!"#
or peak) is dependent on

the magnitude of 𝑒 !!∆! , where Δt is the difference between the time of peak sampling and end of
infusion.

OTHER SOURCES OF ERROR
In addition to the above errors associated with the use of modified versions of the
Sawchuk-Zaske method, there are other potential sources of error that are not unique to this
method of calculation. For example, inaccuracies in recording the exact time of sampling or
dosing could potentially result in significant errors in the final kinetic parameters and the dose.
Further, in some cases, Ro, which is dose/tinf, may be mistaken with the dose. The latter is
especially troublesome if tinf is 0.5 h, resulting in administration of a dose that is twice as much
as the intended dose. Therefore, some protocols advocate the use of 1 h infusions to avoid this
potential problem.

CONCLUSIONS AND RECOMMENDATIONS
Because in clinical settings, the peak and trough samples for aminoglycosides are usually
taken from two consecutive intervals at steady state, it is recommended that clinical
pharmacology curricula expose novice clinicians to this type of calculation during their
education. Further, as simulations in this communication revealed, the degree of error associated
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with the estimation of aminoglycosides V using modified forms of the Sawchuk-Zaske or iv
bolus equations, instead of the original equations, may be significant. Although the experts may
use modified equations, understanding their error ramifications, these modifications may be
confusing to the novice clinicians. Therefore, it is recommended that Equation (4) or (5) be used
without any modification or simplification in calculation of V. As for the design of new dosage
!
regimens, it has to be decided first whether the goal of treatment is to achieve certain 𝐶!"#
and
!
𝐶!"#
or certain trough and peak. If the former is selected, Equations (13) and (15) should be used

for the determination of the dosage interval and infusion rate, respectively. If the latter is
!
selected, the peak and trough must be defined in terms of their time distance from the 𝐶!"#
and
!
𝐶!"#
, respectively. In that case, Equations (14) and (16) may be used for the estimation of the

dosage interval and infusion rate, respectively.
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LEGEND FOR FIGURES

Fig. (1). The differences in the drug plasma/serum concentration-time profiles between iv bolus
dose and short iv infusion methods for a hypothetical case. The same dose is administered in
both cases. Co, concentration immediately after the iv bolus dose; Cmax, concentration
immediately after a short infusion of the same dose; Cmin, the minimum concentration before the
next dose; Peak, the concentration some time (usually 15-60 min) after the end of infusion;
Trough, the concentration some time (usually ≤ 30 min) before Cmin; tinf, the length of short
infusion (usually 30 or 60 min); τ, the length of dosage interval.

Fig. (2). Simulated serum/plasma concentration-time profiles of an example drug adminsitered at
a dose of 80 mg over a 30 min short iv infusion (infusion rate of 160 mg/h) every 8 h. The drug
is administered at 0130, 0930, and 1730 every day with the first dose adminsitered at 0930. A
trough and a peak sample were taken at 0.5 h before and 1.0 h after the start of the seventh short
infusion, respectively (bold circles). Moving the peak backward or the trough forward by one
dosage interval is necessary for estimation of rate constant using Equation (1) in the text.

Fig. (3). Excerpts from a patient’s chart describing the medication and relevant laboratory
results. Additionally, the manipulation of sampling time of trough or peak necessary for accurate
estimation of patient-specific elimination rate constant using Equation (1) is also demonstrated.

Fig. (4). Degree of overestimation of volume of distribution as a function of drug half life when
peak concentration is used in Equation (5) instead of the maximum concentration. The data are
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simulated for three cases with the differences in time (Δt) between the occurrence of maximum
concentration (at the end of infusion) and the peak sampling time being 0.25, 0.5, or 1.0 h. The
length of infusion does not affect the degree of overestimation. The horizontal line demonstrates
an arbitrary error of 10%.

Fig. (5). Degree of overestimation of volume of distribution as a function of drug half life when
iv bolus Equation (10) is used instead of multiple iv infusion Equation (4) or (5). The data are
simulated for three dosage intervals of 4, 6, and 8 h and infusion lengths of 0.5 h (top) and 1.0 h
(bottom). The horizontal line demonstrates an arbitrary error of 10%.

Fig. (6). Degree of overestimation of volume of distribution as a function of drug half life when
the approximation Equation (11) is used instead of the exact Equation (4) or (5). The data are
simulated for three dosage intervals of 4, 6, and 8 h and infusion lengths of 0.5 h (top) and 1.0 h
(bottom). The horizontal line demonstrates an arbitrary error of 10%.
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Excerpts from Medication Administration Record:
Gentamicin 80 mg Q8H
IV infusion over 30 min
Start 4/26/11 0930 1730 0130
Excerpts from Laboratory Report:
Gentamicin Serum Concentration
Date

4/28/11

4/28/11

Time

1030

0900

Concentration (mg/L)

4.68

1.37

Manipulation of Trough or Peak Time
Moving the Trough One Interval Forward
Peak
Trough
Time (hr)
1030
1700
Concentration (mg/L) 4.68
1.37
Moving the Peak One Interval Backward
Peak
Trough
Time (hr)
0230
0900
Concentration (mg/L) 4.68
1.37

Fig. 3
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